Expanding Horizons: Antibody Drug Conjugates in Non-Small Cell Lung Cancer - Episode 1

Overview of Antibody Drug Conjugates in Lung Cancer

,

Wade Thomas Iams, MD, provides an overview of antibody drug conjugates in the treatment of patients with lung cancer, including challenges and impact on clinical practice.

Now Viewing
EP. 1: Overview of Antibody Drug Conjugates in Lung Cancer
EP. 2: ADCs in Development for the Treatment of Lung Cancer
EP. 3: Targeting CEACAM5 in Patients with Non-Small Cell Lung Cancer
EP. 4: HER2-Directed Agents in NSCLC
EP. 5: Targeting HER3 in EGFR-Mutant NSCLC
EP. 6: Exploring TROP2 Expression in Patients with NSCLC

Related Content:

Expanding Horizons: Antibody Drug Conjugates in Non-Small Cell Lung CancerLung Cancer
Daiichi Sankyo, AstraZeneca Withdraw EU MAA for Dato-DXd in Advanced Nonsquamous NSCLC
Defining Resectability in Stage III NSCLC: Addressing Key Controversies
FDA Grants Priority Review to Taletrectinib in ROS1+ Advanced NSCLC